| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Jan 29, 2024 | Sale | $64.14 | 279 | 17,895 | 58,179 | Jan 31, 2024, 04:23 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Jan 30, 2024 | Sale | $65.53 | 971 | 63,630 | 57,208 | Jan 31, 2024, 04:23 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Jan 23, 2024 | Sale | $63.69 | 7,378 | 469,905 | 58,458 | Jan 24, 2024, 04:03 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Jan 22, 2024 | Sale | $65.00 | 1,607 | 104,449 | 65,836 | Jan 23, 2024, 06:05 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Jan 17, 2024 | Sale | $65.58 | 5,207 | 341,475 | 67,443 | Jan 18, 2024, 04:55 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Jan 16, 2024 | Sale | $66.81 | 438 | 29,262 | 72,650 | Jan 17, 2024, 12:24 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Dec 26, 2023 | Sale | $57.86 | 68 | 3,935 | 53,815 | Dec 28, 2023, 04:13 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Dec 27, 2023 | Sale | $60.23 | 235 | 14,154 | 53,580 | Dec 28, 2023, 04:13 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Feb 23, 2023 | Sale | $68.76 | 1,646 | 113,179 | 53,883 | Feb 27, 2023, 04:34 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Feb 21, 2023 | Option Exercise | $58.50 | 825 | 48,263 | 55,529 | Feb 22, 2023, 06:46 AM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Jan 30, 2023 | Sale | $52.76 | 883 | 46,587 | 46,468 | Jan 31, 2023, 04:51 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Jan 27, 2023 | Option Exercise | $52.77 | 367 | 19,367 | 47,351 | Jan 30, 2023, 04:58 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Jan 23, 2023 | Sale | $51.58 | 4,479 | 231,027 | 47,718 | Jan 25, 2023, 04:14 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | Jan 20, 2023 | Option Exercise | $52.05 | 2,033 | 105,818 | 52,197 | Jan 24, 2023, 05:15 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Exec VP, Program Team Lead | Dec 22, 2022 | Option Exercise | $51.68 | 89 | 4,600 | 31,650 | Dec 23, 2022, 04:15 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Exec VP, Program Team Lead | Jan 28, 2022 | Option Exercise | $38.59 | 434 | 16,748 | 32,989 | Feb 01, 2022, 06:09 PM | |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Exec VP, Program Team Lead | Dec 22, 2021 | Option Exercise | $47.82 | 89 | 4,256 | 7,372 | Dec 23, 2021, 04:49 PM |
Menu